Can a diabetes drug help dialysis patients keep their kidneys working?
NCT ID NCT05715814
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a daily 25 mg dose of empagliflozin (a diabetes drug) is safe and helps preserve remaining kidney function in 20 adults on peritoneal dialysis. Participants must still produce at least 250 mL of urine daily. The trial measures changes in kidney filtration rate and looks for a possible rebound effect after stopping the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin (25 mg once daily)
What this could lead to
If it works, this could help people on peritoneal dialysis keep their remaining kidney function longer, potentially reducing dialysis needs.
What could go wrong
This is a small pilot study with only 20 participants, so results may not apply to everyone. Empagliflozin can cause side effects like dehydration or urinary infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY DYSFUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Toronto General Hospital
RECRUITINGToronto, Ontario, M5G2N2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••